CSF markers of neurodegeneration in Parkinson’s disease
- 21 August 2010
- journal article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 117 (10) , 1177-1181
Abstract
Parkinson’s disease (PD) is a chronic, progressive, neurodegenerative disease with a multifactorial etiology. Protein accumulation is speculated by some to play a prominent role in the pathogenesis of PD. The severity of neurodegeneration should correlate with cerebrospinal fluid (CSF) levels of these neurodegenerative markers (NDMs). The aims of the study were to assess the CSF levels of tau protein, beta-amyloid (1–42), cystatin C, and clusterin in patients suffering from PD and in a control group, to compare the CSF levels between the two groups and to correlate them to PD duration. NDMs in the CSF were assessed in 32 patients suffering from PD and in a control group (CG) of 30 patients. The following statistically significant differences in the CSF were found: higher tau protein (p = 0.045) and clusterin levels (p = 0.004) in PD patients versus CG; higher tau protein levels (p = 0.033), tau protein/beta-amyloid (1–42) ratio (p = 0.011), and clusterin (p = 0.044) in patients suffering from PD for <2 years versus patients suffering PD for more than 2 years. No differences between beta-amyloid (1–42) and cystatin C CSF levels were found in the CG and PD patients groups. Significantly higher tau protein and clusterin CSF levels in the group of PD patients with disease duration of <2 years probably reflect the fact that most neurodegenerative changes in PD patients occur in the initial stage of disease.Keywords
This publication has 20 references indexed in Scilit:
- Targets for neuroprotection in Parkinson's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- Cell systems and the toxic mechanism(s) of α-synucleinExperimental Neurology, 2008
- α-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeletonNeurobiology of Disease, 2007
- Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease DementiaDementia and Geriatric Cognitive Disorders, 2006
- CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementiaBrain, 2006
- Protein aggregation in the pathogenesis of familial and sporadic Parkinson's diseaseNeurobiology of Aging, 2006
- Staging of brain pathology related to sporadic Parkinson’s diseaseNeurobiology of Aging, 2003
- Cellular co-localization of phosphorylated tau- and NACP/α-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodiesBrain Research, 1999
- Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson's disease patientsNeuroscience Letters, 1997
- Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.Journal of Neurology, Neurosurgery & Psychiatry, 1992